<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01486017</url>
  </required_header>
  <id_info>
    <org_study_id>015K-CL-PK18</org_study_id>
    <nct_id>NCT01486017</nct_id>
  </id_info>
  <brief_title>A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015K</brief_title>
  <official_title>A Phase 1, Single-Dose, Open-Label, 3-Period, Randomized Crossover Study to Assess the Relative Bioavailability Across Three Strengths of a New ASP015K Tablet Formulation in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the relative bioavailability and pharmacokinetic&#xD;
      profiles from three strengths of a new tablet formulation of ASP015K and to evaluate the&#xD;
      safety and tolerability after a single dose of three different strengths of a new tablet&#xD;
      formulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible subjects will be admitted on Day-1 and remain confined on the unit for 16 days. Each&#xD;
      subject will receive a single dose of study drug per the defined treatment periods on the&#xD;
      mornings of Day 1, Day 6 and Day11. There will be a minimum of 5 days between each&#xD;
      consecutive dose group. Any subject discontinuing the study prior to completion should have&#xD;
      all end of study evaluations completed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of pharmacokinetic parameters of ASP015K: Cmax, AUClast, and AUCinf</measure>
    <time_frame>Up to Day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of pharmacokinetic parameters of ASP015K: tmax, apparent terminal elimination half-life (t1/2), apparent body clearance after oral dosing (CL/F), and apparent volume of distribution (Vz/F)</measure>
    <time_frame>Up to Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of pharmacokinetic parameters of ASP015K metabolite H2: Cmax, AUClast, AUCinf, tmax and t1/2</measure>
    <time_frame>Up to Day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Bioavailability of ASP015K</condition>
  <condition>Pharmacokinetics of ASP015K</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASP015K oral dose low strength</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASP015K oral dose medium strength</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASP015K oral dose high strength</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP015K</intervention_name>
    <description>oral</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject weighs at least 45 kg and has a body mass index (BMI) of 18-32 kg/m2&#xD;
&#xD;
          -  Male subject agrees to sexual abstinence, is surgically sterile or is using a&#xD;
             medically acceptable method to prevent pregnancy and agrees to continue using this&#xD;
             method until 90 days after the last dose of study drug administration&#xD;
&#xD;
          -  Male subject agrees to not donate sperm until 90 days after the dose of study drug&#xD;
             administration&#xD;
&#xD;
          -  Female subject is surgically sterile or is post-menopausal and is not pregnant and is&#xD;
             not lactating&#xD;
&#xD;
          -  Subject's 12-lead electrocardiogram (ECG) is normal&#xD;
&#xD;
          -  Subject must be capable of swallowing multiple tablets&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has a previous history of any clinically significant gastro-intestinal,&#xD;
             neurological, renal, hepatic, pulmonary, metabolic, cardiovascular, psychiatric,&#xD;
             endocrine, hematological disorder or disease, malignancy excluding non-melanoma skin&#xD;
             cancer or any other medical condition&#xD;
&#xD;
          -  Subject has had major GI surgery (such as colectomy, cholecystectomy, etc)&#xD;
&#xD;
          -  Subject has a history of consuming more than 14 units of alcoholic beverages per week&#xD;
             or has a history of alcoholism or drug/chemical/ substance abuse within past 2 years&#xD;
&#xD;
          -  Subject has/had a symptomatic, viral, bacterial (including upper respiratory&#xD;
             infection), or fungal (non-cutaneous) infection within 1 week&#xD;
&#xD;
          -  Subject has a positive test for hepatitis C antibody, or positive test for hepatitis B&#xD;
             surface antigen (HBsAg), or positive hepatitis B core antibody&#xD;
&#xD;
          -  Subject has a history of the human immunodeficiency virus (HIV) antibody&#xD;
&#xD;
          -  Subject has a positive tuberculosis (TB) skin test, Quantiferon Gold test or T-SPOTÂ®&#xD;
             test&#xD;
&#xD;
          -  Subject received any vaccine within 60 days&#xD;
&#xD;
          -  Subject received an experimental agent within 30 days&#xD;
&#xD;
          -  Subject has an absolute neutrophil count (ANC) &lt; 2500 cells/mm3&#xD;
&#xD;
          -  Subject has had any significant blood loss, donated one unit (450 mL) of blood or&#xD;
             more, or received a transfusion of any blood or blood products within 60 days or&#xD;
             donated plasma within 7 days&#xD;
&#xD;
          -  Subject has a history of smoking or has used tobacco-containing products and nicotine&#xD;
             or nicotine-containing products in the past six months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>December 1, 2011</study_first_submitted>
  <study_first_submitted_qc>December 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2011</study_first_posted>
  <last_update_submitted>December 2, 2011</last_update_submitted>
  <last_update_submitted_qc>December 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASP015K</keyword>
  <keyword>healthy subjects</keyword>
  <keyword>bioavailability</keyword>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>psoriasis</keyword>
  <keyword>transplantation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peficitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

